Key result
Congenital LQTS treatment is linked to ~95% lower one-year mortality versus no treatment.
Why the study?
Timely diagnosis and effective clinical management are critical in CLQTS given high untreated mortality, and emerging evidence has revealed diverse genetic mutations, pathophysiologic triggers, and phenotypic subtypes.
Untreated Congenital Long QT Syndrome has a high 1-year mortality rate of approximately 20%, which is reduced to <1% with effective clinical management.
Answers are grounded in this paper and cite their sources.
Supports treating congenital long QT syndrome; leaves open randomized confirmation of survival benefit.
Congenital Long QT Syndrome (CLQTS) is the most common inherited arrhythmia. The QT interval, which marks the duration of ventricular depolarization and repolarization in the myocardium, can be prolonged due to mutations in genes coding for the ion channel proteins that govern the cardiac action potential. The lengthening of the QT interval can lead to a wide range of clinical symptoms, including seizures, torsades de pointes, and fatal arrhythmias. There is a growing body of evidence that has revealed the genetic mutations responsible for the pathophysiology of CLQTS, and this has led to hypotheses regarding unique triggers and clinical features associated with specific gene mutations. Epidemiologic evidence has revealed a 1-year mortality rate of approximately 20% in untreated CLQTS patients, and a <1% of 1-year mortality rate in treated patients, underscoring the importance of timely diagnosis and effective clinical management. There are many phenotypic syndromes that constitute CLQTS, including but not limited to, Jervell and Lange-Nielsen syndrome, Romano and Ward syndrome, Andersen-Tawil syndrome, and Timothy syndrome. In this review, we aim to (1) summarize the genetic, epidemiologic, and pathophysiological basis of CLQTS and (2) outline the unique features of the phenotypic subtypes and their clinical management.
No takes yet. Share an insight, caveat, or question.
Pandit et al. (2022) conducted a review in Congenital Long QT Syndrome. Treatment of Congenital Long QT Syndrome is associated with a <1% 1-year mortality rate, compared to approximately 20% in untreated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: